Adam Knight

Adam has always been fascinated by genetics—and when his grandmother was diagnosed with Parkinson’s disease (PD) during his freshman year of college, he sharpened his focus. “From then on, I basically lived in the research lab,” he explains.

Adam received his BS and MS degrees from the University of Alabama, and his PhD from the University of Cambridge as part of the NIH-Oxford/Cambridge Scholars Program.

For ten years, his research focused on the genetic basis of neurodegenerative disease, including PD. He has published a dozen papers on the topic in high impact scientific journals, including multiple Cell papers.

After completing his PhD, Adam joined IQVIA where he worked on projects ranging from development and commercial strategy for Top 5 pharma companies to helping small biotech companies raise funding. After IQVIA, Adam joined Lentigen, where he received hands-on experience in both R&D and business development.

In September 2017, Adam joined Kleiner Perkins to create a biotech company with Beth Seidenberg, which became Neuron23, a firm committed to leveraging recent innovations in Artificial Intelligence (AI) and genetics to develop therapies for genetic disorders. In 2018, Adam and Beth launched Neuron23 in partnership with Origenis, a German biotech company with a portfolio of five small molecule therapies. Origenis had created a state-of-the-art AI-based drug discovery platform, and their lead program targeted LRRK2.

Over the next ten years, Adam has ambitious plans to build Neuron23 into a powerhouse biotechnology company.